Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to share the exciting progress made by its A$18.7m clinical-industrial partnership with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR).
Highlights
- Osteopore’s A$18.7m partnership with Singapore’s NDCS and A*STAR to develop next-generation dental implants achieves key milestones.
- The project developed a 3D-printing technology which can successfully combine patented biological additives and polymer compounds.
- The successful combination of the additives and compounds can speed up bone regeneration.
- Adverse reaction testing demonstrated the non-cytotoxicity of successfully combining patented biological additives and polymer compounds.
- Testing for osteogenic differentiation revealed enhanced osteogenic differentiation capabilities.
- The project is now set to advance to in vivo studies of biological models, to gauge the efficacy of bone regeneration.
- The next-generation dental implants provide Osteopore with exposure to the US$27.55 billion global dental bone graft and membrane substitute market.
On 13 December 2021, Osteopore announced the signing of an agreement with NDCS and A*STAR to launch an A$18.7m dental implant project.
The project’s key milestones – see announcement dated 13 December 2021 – included combining patented biological additives and polymer compounds to test for adverse reactions, osteogenic differentiation to indicate bone growth, and higher osteogenic differentiation to demonstrate faster bone growth.
The Company is pleased to announce the successful development of a 3D-printed technology, which can combine patented biological additives and polymer compounds for dental implants that have the potential to accelerate bone healing.
Adverse reaction testing demonstrated that the successful combination of patented biological additives and polymer compounds was non-cytotoxic, showing no adverse reactions and good biocompatibility.
Moreover, osteogenic differentiation testing showed enhanced viability and osteogenic differentiation capabilities, indicating both osteogenic differentiation and higher osteogenic differentiation.
The next-generation dental implant project is now set to progress towards in vivo studies in biological models.
Commenting on the NDCS and A*STAR partnership and the project’s early successes, CEO Dr Yujing Lim said:
“We are excited by the outcomes of this project so far and appreciate the support of our partners at A*STAR and NDCS. We are delighted with the dedication of our partners towards ensuring that project milestones are met.”
“While we continue to prioritise our objective of commercialising our current products, we are looking forward to working on new technologies – such as the next-generation jaw implant – which supports our long-term vision of becoming the global leader in regenerative medicine,” said Dr Lim.
The global dental bone graft and membrane substitutes market was valued at USD$11.47 billion in 2023, with a projected value of USD$27.55 billion by 2030 according to Verified Market Reports.
